Quarterly ResultMay 12, 2026, 04:14 PM
Orchestra BioMed Q1 Net Loss $(20.7)M; Revenue Down 87%
AI Summary
Orchestra BioMed Holdings, Inc. reported a net loss of $20.7 million for Q1 2026, an increase from $18.8 million in Q1 2025. Total revenue significantly decreased by 87% to $0.11 million, primarily due to the absence of partnership revenue. The company recognized a $2.2 million gain from the sale of strategic investments and raised $5.9 million through an At-The-Market offering. Despite the higher net loss, basic and diluted net loss per share improved to $(0.33) from $(0.49) due to an increase in weighted-average shares outstanding.
Key Highlights
- Net loss increased to $(20.7)M in Q1 2026 from $(18.8)M in Q1 2025.
- Total revenue decreased 87% to $0.11M in Q1 2026 from $0.87M in Q1 2025.
- Partnership revenue was $0 in Q1 2026, down from $0.73M in Q1 2025.
- Recognized a $2.2M gain from the sale of strategic investments in Q1 2026.
- Net cash used in operating activities increased to $(22.2)M in Q1 2026.
- Raised $5.9M from an At-The-Market offering in Q1 2026.
- Cash and cash equivalents were $28.4M as of March 31, 2026.
- Accumulated deficit reached $383.3M as of March 31, 2026.